Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Multiple Myeloma 4Smoldering Multiple Myeloma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neoplasm, Residual 1Neoplasm Metastasis 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Follicular 1Lung Neoplasms 1Leukemia, Promyelocytic, Acute 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Cisplatin 33Radiotherapy 23Cetuximab 18Paclitaxel 14Docetaxel 14pembrolizumab 13Carboplatin 12Fluorouracil 10Radiotherapy, Intensity-Modulated 8Nivolumab 8Drug Therapy 7Erlotinib Hydrochloride 6Panitumumab 5dacomitinib 4Radiation 4Methotrexate 4Esophagectomy 4130-nm albumin-bound paclitaxel 4durvalumab 3ON 01910 3Leucovorin 3Gemcitabine 3Chemoradiotherapy 3vandetanib 2palbociclib 2osimertinib 2nedaplatin 2fludarabine 2cabazitaxel 2atezolizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Carcinoma, Squamous Cell × Maintenance × Clear all
NCT02027428 2020-08-17

Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer

Celgene

Phase 3 Completed
427 enrolled 29 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡